Use of Axitinib and analogs thereof in preparing blood-brain barrier permeability regulator
US12419875B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 9, 2019 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Jun 13, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a use of Axitinib and analogs thereof in the preparation of a blood-brain barrier permeability regulator. The blood-brain barrier permeability regulator can reduce blood-brain barrier permeability, and promote recovery of a blood-brain barrier function from a pathologically impaired state to a state close to a physiological barrier. Axitinib and an analog thereof reduce blood-brain barrier permeability by inhibiting the vascular endothelial cell growth factor-phosphatidylinositol kinase-protein kinase B signaling pathway and reducing the degree to which a blood-brain barrier tight junction protein Claudin-5/Occludin is down-regulated. The blood-brain barrier permeability regulator can be used in the treatment of a disease related to causing a change in blood-brain barrier permeability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.